BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-83@catalystbrief.girapphe.com
DTSTAMP:20261117T061556Z
LAST-MODIFIED:20261117T061556Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Biohaven Therapeutics Ltd. — BHV-7000 [Dec 2026]
DESCRIPTION:Phase 3 primary completion: A Study to Determine if BHV-7000 is
  Effective and Safe in Adults With Refractory Focal Onset Epilepsy.\nSourc
 e: https://clinicaltrials.gov/study/NCT06132893\nhttps://catalystbrief.gir
 apphe.com/e/83?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/83?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
